An experimental drug blocked a cancer gene in lab and animal tests
Original title: Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only tested in lab dishes and animals, not in people.
The short version
An early drug called RO3903 shrank tumors in animals, including tumors in the brain.
What was studied. Scientists compared drugs that block a changed gene called KRAS G12C. They tested a new one, RO3903, in lab tests and in animal tumor models, including a model with tumors inside the brain.
What they found. Some KRAS drugs stop working because the gene switches back to a form the drug cannot grab. RO3903 locked onto the target fast and kept working in those cases. It slowed tumor growth in several animal models, and higher doses worked better. It also worked well when paired with other cancer drugs and with immune drugs.
What this means, and what it doesn't
What it could mean: The changed KRAS G12C gene drives some cancers. This work points to a way to get past drugs that stop working over time. The brain tumor animal result suggests the drug may reach the brain. For now this is a research tool, not care a doctor can give.
What it doesn't mean: This does not mean a new treatment is here. The work was done in lab dishes and animals, not in people. No one knows yet if it is safe or if it helps humans. Drugs that work in animals often fail in people. Years of human testing would come first. This is not a cure and not a promise of one.
Source: PubMed, November 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.